PubRank

Radiofrequency (RF) Ablation for Atrial Fibrillation (AF) in Patients With Heart Failure With Preserved Ejection Fraction (AF-HFpEF)

Clinical Trial ID NCT04327596

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT04327596

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999 29.32
2 Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006 17.13
3 The Patient-Reported Outcomes Measurement Information System (PROMIS): progress of an NIH Roadmap cooperative group during its first two years. Med Care 2007 13.29
4 A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001 9.75
5 Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008 9.62
6 Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med 1987 8.77
7 Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003 8.12
8 Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014 7.48
9 Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000 6.08
10 Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail 2013 4.98
11 Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol 2008 4.83
12 The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006 4.10
13 Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise. Circulation 1996 3.98
14 Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol 2002 2.50
15 Atrial Fibrillation Begets Heart Failure and Vice Versa: Temporal Associations and Differences in Preserved Versus Reduced Ejection Fraction. Circulation 2016 1.76
16 Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013 1.30
17 Early management of atrial fibrillation to prevent cardiovascular complications. Eur Heart J 2014 1.29
18 Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol 2014 1.27
19 Echocardiographic diastolic parameters and risk of atrial fibrillation: the Cardiovascular Health Study. Eur Heart J 2011 1.17
20 Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2012 1.02
21 Comparable performance of the Kansas City Cardiomyopathy Questionnaire in patients with heart failure with preserved and reduced ejection fraction. Circ Heart Fail 2013 0.87
22 Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Vicious Twins. J Am Coll Cardiol 2016 0.75
23 History of atrial fibrillation as a risk factor in patients with heart failure and preserved ejection fraction. Circ Heart Fail 2014 0.75
24 Feasibility of a Tablet Computer System to Collect Patient-reported Symptom Severity in Patients Undergoing Diagnostic Coronary Angiography. Crit Pathw Cardiol 2015 0.75
25 Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC Heart Fail 2017 0.75
Next 100